SE7606968L - Forfarande for framstellning av intravenos nativ-humanimmunglobulin med naturlig halveringstid - Google Patents

Forfarande for framstellning av intravenos nativ-humanimmunglobulin med naturlig halveringstid

Info

Publication number
SE7606968L
SE7606968L SE7606968A SE7606968A SE7606968L SE 7606968 L SE7606968 L SE 7606968L SE 7606968 A SE7606968 A SE 7606968A SE 7606968 A SE7606968 A SE 7606968A SE 7606968 L SE7606968 L SE 7606968L
Authority
SE
Sweden
Prior art keywords
natural
serum
intravenos
humanimmunglobulin
preparing
Prior art date
Application number
SE7606968A
Other languages
English (en)
Swedish (sv)
Inventor
W Stephan
Original Assignee
Biotest Serum Institut Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotest Serum Institut Gmbh filed Critical Biotest Serum Institut Gmbh
Publication of SE7606968L publication Critical patent/SE7606968L/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y10S530/831—Cohn fractions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE7606968A 1975-06-18 1976-06-17 Forfarande for framstellning av intravenos nativ-humanimmunglobulin med naturlig halveringstid SE7606968L (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2527064A DE2527064C3 (de) 1975-06-18 1975-06-18 Verfahren zur Herstellung eines intravenösen Nativ-Human-Immunglobulin-Präparates mit natürlicher Halbwertszeit und gegenüber dem Ausgangsmaterial unveränderten Antikörperaktivität

Publications (1)

Publication Number Publication Date
SE7606968L true SE7606968L (sv) 1976-12-19

Family

ID=5949318

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7606968A SE7606968L (sv) 1975-06-18 1976-06-17 Forfarande for framstellning av intravenos nativ-humanimmunglobulin med naturlig halveringstid

Country Status (11)

Country Link
US (1) US4082734A (show.php)
JP (1) JPS521013A (show.php)
AT (1) AT356265B (show.php)
BE (1) BE841950A (show.php)
CA (1) CA1053153A (show.php)
CH (1) CH628518A5 (show.php)
DE (1) DE2527064C3 (show.php)
FR (1) FR2314730A1 (show.php)
GB (1) GB1535977A (show.php)
NL (1) NL7606581A (show.php)
SE (1) SE7606968L (show.php)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK139056B (da) * 1976-04-06 1978-12-11 Nordisk Insulinlab Fremgangsmåde til udvinding af immunoglobulin, der er egnet til intravenøs indgivelse.
US4164495A (en) * 1976-04-06 1979-08-14 Nordisk Insulinlaboratorium Method of recovering immunoglobulin using a polyol and an alkanoic acid
DE2658334C3 (de) * 1976-12-23 1987-05-07 Behringwerke Ag, 3550 Marburg Verfahren zum Herstellen von Immunglobulinpräparationen mit verminderter Komplementaktivität und ein diese enthaltendes Arzneimittel
US4374763A (en) * 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4305871A (en) * 1980-09-02 1981-12-15 Edward Shanbrom Method of selectively increasing yield and purity of certain cryoprecipitate proteins by heating
US4499073A (en) * 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
ATE19735T1 (de) * 1982-02-08 1986-05-15 Schweiz Serum & Impfinst Intravenoes verabreichbares humanes immunglobulin und verfahren zu dessen herstellung.
DE3310150A1 (de) * 1983-03-21 1984-09-27 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Verfahren zur herstellung einer nebenwirkungsfreien igg-immunglobulinloesung fuer die intravenoese applikation
DE3344656A1 (de) * 1983-12-09 1985-06-13 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Verfahren zur herstellung einer serumproteinloesung
CH662824A5 (de) * 1984-02-14 1987-10-30 Graf & Co Ag Kardiersegment.
AU6948787A (en) * 1986-03-10 1987-09-28 Rubinstein, A.I. A method for treating gammaglobulin
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
DE3927111C3 (de) * 1989-08-17 1994-09-01 Biotest Pharma Gmbh Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate
US5256771A (en) * 1990-04-03 1993-10-26 Miles Inc. Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation
US5219578A (en) * 1991-02-25 1993-06-15 Innovet, Inc. Composition and method for immunostimulation in mammals
BE1012448A3 (fr) * 1998-12-07 2000-11-07 S C R L Dept Central De Fracti Standard utilise dans des tests de diagnostic et/ou de quantification.
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US6893639B2 (en) * 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
WO2016033382A1 (en) * 2014-08-27 2016-03-03 Capnia, Inc. Methods for immune globulin administration

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1198277A (en) 1967-09-05 1970-07-08 Ustav Ser A Ockovacich Latek O Process for the Preparation of Serum Gamma Globulins by Fractionation of Blood Serum, Plasma or Raw Serum Fractions with Quaternary Ammonium Compounds
DE1792555C3 (de) 1968-09-19 1980-01-10 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung einer für die intravenöse Anwendung geeigneten Gammaglobulinlösung
US3916026A (en) * 1968-09-19 1975-10-28 Biotest Serum Institut Gmbh Method for the preparation of gamma-globulin suitable for intravenous use
US3763135A (en) * 1971-11-08 1973-10-02 Baxter Laboratories Inc Gamma globulin production from cohn fraction iii using polyethylene glycol
CA1007568A (en) * 1973-12-13 1977-03-29 Michael C. Attwell Bovine immunoglobulin isolation process

Also Published As

Publication number Publication date
CA1053153A (en) 1979-04-24
JPS5516488B2 (show.php) 1980-05-02
GB1535977A (en) 1978-12-13
CH628518A5 (de) 1982-03-15
FR2314730A1 (fr) 1977-01-14
FR2314730B1 (show.php) 1978-12-15
DE2527064C3 (de) 1979-11-15
NL7606581A (nl) 1976-12-21
AT356265B (de) 1980-04-25
JPS521013A (en) 1977-01-06
DE2527064B2 (de) 1979-03-29
BE841950A (fr) 1976-09-16
ATA395576A (de) 1979-09-15
DE2527064A1 (de) 1976-12-23
US4082734A (en) 1978-04-04

Similar Documents

Publication Publication Date Title
SE7606968L (sv) Forfarande for framstellning av intravenos nativ-humanimmunglobulin med naturlig halveringstid
Katamine et al. Epstein–Barr virus transforms precursor B cells even before immunoglobulin gene rearrangements
Reynolds et al. Inhibition of B lymphocyte activation by interferon-gamma.
BIELORY et al. Human serum sickness: a prospective analysis of 35 patients treated with equine anti-thymocyte globulin for bone marrow failure
US5182257A (en) Use of pure histones h1 and h2a:h2b dimers in therapeutic methods
CA1142466A (en) Cell lines
ES8601983A1 (es) Procedimiento para preparar derivados de tiazol
Bazin et al. Differential effect of neonatal injections of Anti-µ or Anti-δ antibodies on the synthesis of IgM, IgD, IgE, IgA, IgG1, IgG2a, IgG2b, and IgG2c immunoglobulin classes
ES515177A0 (es) Procedimiento para el tratamiento de inmunoglobulina de suero.
Kai et al. Studies on the immunopotentiating effects of a streptococcal preparation, OK-432. I. Enhancement of T cell-mediated immune responses of mice
US3928580A (en) Injectable glycoproteins containing terminal {37 C{38 {0 ends of human immunoglobulins
DeBoer et al. Natural cytotoxicity and antibody-dependent cytotoxicity in solid tumor cancer patients: Regulation by adherent cells
Wood et al. Receptor sites for antigen-antibody complexes on cells derived from solid tumors: Detection by means of antibody sensitized sheep erythrocytes labeled with technetium-99m
Rapoport et al. Host enzyme induction of bacterial infection
GB1528259A (en) Process for the preparation of a gamma-globulin solution suitable for intravenous administration
Taylor et al. Control of immune interferon release by cytotoxic T-cell clones specific for influenza
Masuoka et al. Conversion of C14-Arterenol to Epinephrine in vivo.
Stutman et al. H–2 restriction and non-restriction of T-cell-mediated cytotoxicity against mouse mammary tumour targets
Defendi Macrophage cell lines and their uses in immunobiology
GB1399824A (en) Heparin esters
Coico et al. Physiology of IgD. VIII. Age-related decline in the capacity to generate T cells with receptors for IgD and partial reversal of the defect with IL 2.
JP2627076B2 (ja) 抗破傷風毒素ヒト型モノクローナル抗体、それを利用した破傷風毒素中和剤及びヒト型モノクローナル抗体産生ハイブリドーマ
CA2071520C (en) Elimination of activated lymphocytes
GB1351535A (en) Isopropylamino pyrimidine derivatives
JPS567721A (en) Preparation of immunoglobulin for intravenous injection

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 7606968-1